| By Marketwire . | Article Rating: |
|
| November 26, 2012 09:40 AM EST | Reads: |
235 |
MESA, AZ -- (Marketwire) -- 11/26/12 -- Matthew Likens, president and CEO of Ulthera, Inc. -- a global, high-growth medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology -- is scheduled to present at two upcoming healthcare conferences:
- Wednesday, Nov. 28 at 9:10 a.m. EST
24th Annual Piper Jaffray Healthcare Conference in New York City, Nov. 27-28, 2012
Location: The New York Palace Hotel, 455 Madison Avenue, New York, NY
- Tuesday, Dec. 4 at 2:30 p.m. EST
6th Annual Canaccord Genuity Medical Technology & Diagnostics Forum in New York, Dec. 4, 2012
Location: Le Parker Meridien, 119 West 56th Street, New York, NY
Likens will present an overview of the company as well as its accomplishments to date and prospects for the future.
About Ulthera
Ulthera, Inc. is a global, high-growth medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology. The Ulthera® System is the first and only energy-based device to receive FDA clearance for a non-invasive aesthetic lift indication. It is used in a face and neck procedure known as Ultherapy®, which is cleared to lift skin on the brow, neck and under the chin. Founded in 2004 and based in Mesa, Ariz., Ulthera is a privately held company backed by top-tier venture capital firms, New Enterprise Associates and Apposite Capital. For more information, visit www.ultherapy.com.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Media Contact:
Lindsey Karberg
Ulthera, Inc.
480.336.1744
Email Contact
Published November 26, 2012 Reads 235
Copyright © 2012 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.
More Stories By Marketwire .
Copyright © 2009 Marketwire. All rights reserved. All the news releases provided by Market Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

